| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium Infections | 95 | 2025 | 251 | 26.290 |
Why?
|
| Anti-Bacterial Agents | 94 | 2025 | 2575 | 10.010 |
Why?
|
| Vancomycin | 26 | 2025 | 236 | 5.610 |
Why?
|
| Cross Infection | 24 | 2022 | 344 | 5.320 |
Why?
|
| Antifungal Agents | 22 | 2023 | 305 | 4.380 |
Why?
|
| Ribotyping | 23 | 2025 | 49 | 4.240 |
Why?
|
| Microbial Sensitivity Tests | 47 | 2025 | 835 | 3.930 |
Why?
|
| Gastrointestinal Microbiome | 15 | 2025 | 822 | 3.870 |
Why?
|
| Candidemia | 12 | 2023 | 43 | 3.760 |
Why?
|
| Candida | 14 | 2023 | 84 | 3.690 |
Why?
|
| Bacterial Toxins | 24 | 2024 | 177 | 3.640 |
Why?
|
| Enterocolitis, Pseudomembranous | 21 | 2022 | 93 | 3.630 |
Why?
|
| Feces | 25 | 2025 | 783 | 3.240 |
Why?
|
| Diarrhea | 21 | 2023 | 339 | 3.030 |
Why?
|
| Anti-Infective Agents | 13 | 2024 | 276 | 2.670 |
Why?
|
| Pharmacy Service, Hospital | 9 | 2018 | 54 | 2.630 |
Why?
|
| Pseudomonas aeruginosa | 12 | 2012 | 180 | 2.620 |
Why?
|
| Candidiasis | 13 | 2023 | 138 | 2.580 |
Why?
|
| Bile Acids and Salts | 5 | 2025 | 257 | 2.560 |
Why?
|
| Echinocandins | 9 | 2023 | 44 | 2.560 |
Why?
|
| Microbiota | 5 | 2025 | 443 | 2.440 |
Why?
|
| Pharmacists | 10 | 2020 | 104 | 2.410 |
Why?
|
| Tetracyclines | 6 | 2025 | 22 | 2.380 |
Why?
|
| Antimicrobial Stewardship | 5 | 2020 | 89 | 2.260 |
Why?
|
| Bacteremia | 12 | 2019 | 429 | 2.230 |
Why?
|
| Gram-Positive Bacteria | 5 | 2019 | 49 | 2.200 |
Why?
|
| Bacterial Proteins | 20 | 2025 | 924 | 2.110 |
Why?
|
| Humans | 234 | 2025 | 133373 | 2.090 |
Why?
|
| Drug Resistance, Bacterial | 14 | 2024 | 384 | 2.090 |
Why?
|
| Fluconazole | 8 | 2012 | 50 | 2.020 |
Why?
|
| Bacteria | 8 | 2022 | 537 | 1.880 |
Why?
|
| Rifamycins | 8 | 2013 | 22 | 1.860 |
Why?
|
| Environmental Microbiology | 5 | 2019 | 16 | 1.710 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2025 | 294 | 1.570 |
Why?
|
| Bacterial Infections | 7 | 2018 | 329 | 1.520 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2018 | 79 | 1.520 |
Why?
|
| Medication Errors | 4 | 2019 | 207 | 1.500 |
Why?
|
| Patient Discharge | 4 | 2022 | 521 | 1.480 |
Why?
|
| Metronidazole | 11 | 2025 | 149 | 1.460 |
Why?
|
| Middle Aged | 78 | 2025 | 28985 | 1.450 |
Why?
|
| Pseudomonas Infections | 5 | 2010 | 122 | 1.360 |
Why?
|
| Aged | 69 | 2025 | 21500 | 1.360 |
Why?
|
| Blood Culture | 3 | 2019 | 36 | 1.340 |
Why?
|
| Antibiotic Prophylaxis | 5 | 2011 | 129 | 1.310 |
Why?
|
| Health Care Costs | 6 | 2019 | 409 | 1.250 |
Why?
|
| Male | 101 | 2025 | 65592 | 1.240 |
Why?
|
| Female | 102 | 2025 | 71503 | 1.220 |
Why?
|
| Purine Nucleosides | 4 | 2025 | 11 | 1.220 |
Why?
|
| Adult | 65 | 2025 | 31684 | 1.220 |
Why?
|
| Ceftriaxone | 2 | 2020 | 70 | 1.210 |
Why?
|
| Spores, Bacterial | 6 | 2022 | 24 | 1.200 |
Why?
|
| Candidiasis, Invasive | 2 | 2022 | 23 | 1.190 |
Why?
|
| Candida glabrata | 5 | 2018 | 20 | 1.140 |
Why?
|
| Fatty Acids, Volatile | 2 | 2025 | 47 | 1.140 |
Why?
|
| Carbapenems | 4 | 2020 | 43 | 1.130 |
Why?
|
| Lipopeptides | 8 | 2025 | 36 | 1.130 |
Why?
|
| Texas | 28 | 2021 | 3666 | 1.130 |
Why?
|
| Antidiarrheals | 3 | 2013 | 19 | 1.110 |
Why?
|
| Proanthocyanidins | 3 | 2013 | 8 | 1.110 |
Why?
|
| Aged, 80 and over | 30 | 2025 | 7141 | 1.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2018 | 151 | 1.080 |
Why?
|
| Community-Acquired Infections | 4 | 2022 | 247 | 1.050 |
Why?
|
| Prebiotics | 2 | 2025 | 29 | 1.000 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 76 | 0.980 |
Why?
|
| Length of Stay | 13 | 2019 | 1393 | 0.970 |
Why?
|
| Community Pharmacy Services | 3 | 2020 | 9 | 0.970 |
Why?
|
| Hospitals | 8 | 2021 | 441 | 0.970 |
Why?
|
| Fecal Microbiota Transplantation | 4 | 2025 | 106 | 0.960 |
Why?
|
| Dietary Fiber | 1 | 2025 | 82 | 0.930 |
Why?
|
| Dog Diseases | 3 | 2022 | 58 | 0.930 |
Why?
|
| DNA Polymerase III | 1 | 2025 | 29 | 0.920 |
Why?
|
| Enterotoxins | 11 | 2023 | 82 | 0.910 |
Why?
|
| Benchmarking | 2 | 2016 | 146 | 0.910 |
Why?
|
| Students, Pharmacy | 5 | 2020 | 72 | 0.900 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2024 | 120 | 0.890 |
Why?
|
| Faculty | 3 | 2014 | 109 | 0.870 |
Why?
|
| Education, Pharmacy | 5 | 2020 | 60 | 0.840 |
Why?
|
| beta-Lactamases | 4 | 2011 | 212 | 0.840 |
Why?
|
| Healthy Volunteers | 4 | 2025 | 153 | 0.820 |
Why?
|
| Proton Pump Inhibitors | 2 | 2024 | 275 | 0.810 |
Why?
|
| Neutrophils | 2 | 2024 | 362 | 0.810 |
Why?
|
| Disinfection | 4 | 2019 | 29 | 0.810 |
Why?
|
| Fluoroquinolones | 5 | 2023 | 97 | 0.810 |
Why?
|
| Hospitalization | 9 | 2021 | 1921 | 0.800 |
Why?
|
| Hospitals, University | 8 | 2014 | 107 | 0.790 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2020 | 230 | 0.780 |
Why?
|
| Actinobacteria | 1 | 2022 | 13 | 0.780 |
Why?
|
| Recurrence | 11 | 2023 | 1469 | 0.770 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 3105 | 0.770 |
Why?
|
| Prospective Studies | 23 | 2023 | 6582 | 0.760 |
Why?
|
| Protease Inhibitors | 2 | 2021 | 100 | 0.750 |
Why?
|
| Medical Order Entry Systems | 3 | 2019 | 113 | 0.740 |
Why?
|
| Equipment Contamination | 2 | 2019 | 41 | 0.740 |
Why?
|
| Schools, Pharmacy | 5 | 2020 | 26 | 0.730 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2018 | 306 | 0.720 |
Why?
|
| Biofilms | 4 | 2020 | 99 | 0.720 |
Why?
|
| Pharmacy Residencies | 3 | 2020 | 6 | 0.710 |
Why?
|
| Surgical Wound Infection | 4 | 2007 | 273 | 0.710 |
Why?
|
| Lopinavir | 1 | 2021 | 7 | 0.700 |
Why?
|
| Risk Factors | 26 | 2023 | 10954 | 0.690 |
Why?
|
| Ritonavir | 1 | 2021 | 46 | 0.680 |
Why?
|
| Pharmacy | 1 | 2020 | 20 | 0.680 |
Why?
|
| Acinetobacter baumannii | 2 | 2011 | 47 | 0.680 |
Why?
|
| Pharmaceutical Services | 5 | 2020 | 38 | 0.670 |
Why?
|
| Floors and Floorcoverings | 2 | 2017 | 3 | 0.670 |
Why?
|
| Blood Pressure | 2 | 2025 | 1411 | 0.660 |
Why?
|
| Macrophages | 1 | 2024 | 697 | 0.660 |
Why?
|
| Molecular Epidemiology | 5 | 2021 | 147 | 0.660 |
Why?
|
| Prevalence | 11 | 2023 | 2632 | 0.660 |
Why?
|
| Amphotericin B | 4 | 2012 | 91 | 0.660 |
Why?
|
| Shoes | 2 | 2017 | 24 | 0.640 |
Why?
|
| beta-Lactam Resistance | 3 | 2011 | 49 | 0.640 |
Why?
|
| Hypertension | 2 | 2025 | 1403 | 0.630 |
Why?
|
| Animals, Zoo | 1 | 2019 | 17 | 0.630 |
Why?
|
| Vancomycin Resistance | 5 | 2024 | 22 | 0.620 |
Why?
|
| Program Development | 2 | 2020 | 190 | 0.610 |
Why?
|
| Clarithromycin | 3 | 2008 | 120 | 0.600 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 562 | 0.600 |
Why?
|
| Multivariate Analysis | 9 | 2019 | 1463 | 0.600 |
Why?
|
| Retrospective Studies | 26 | 2023 | 17568 | 0.590 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 48 | 0.590 |
Why?
|
| Intensive Care Units | 5 | 2014 | 542 | 0.590 |
Why?
|
| Polymerase Chain Reaction | 9 | 2020 | 1583 | 0.590 |
Why?
|
| Rifampin | 2 | 2010 | 136 | 0.590 |
Why?
|
| Drug Compounding | 1 | 2018 | 43 | 0.580 |
Why?
|
| Respiratory Tract Infections | 2 | 2017 | 296 | 0.580 |
Why?
|
| Communicable Diseases | 5 | 2021 | 164 | 0.570 |
Why?
|
| Drug Resistance, Fungal | 3 | 2014 | 30 | 0.560 |
Why?
|
| Peritonitis | 1 | 2018 | 79 | 0.560 |
Why?
|
| Cohort Studies | 17 | 2024 | 5199 | 0.550 |
Why?
|
| Surveys and Questionnaires | 9 | 2023 | 3988 | 0.550 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 350 | 0.550 |
Why?
|
| Staphylococcus aureus | 3 | 2012 | 480 | 0.540 |
Why?
|
| Neoplasms | 5 | 2023 | 2992 | 0.540 |
Why?
|
| Urban Population | 3 | 2019 | 241 | 0.530 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 203 | 0.530 |
Why?
|
| Fungal Proteins | 2 | 2015 | 143 | 0.530 |
Why?
|
| Coronary Artery Bypass | 4 | 2008 | 535 | 0.520 |
Why?
|
| Disease Transmission, Infectious | 2 | 2019 | 87 | 0.520 |
Why?
|
| Decontamination | 1 | 2016 | 13 | 0.520 |
Why?
|
| Quality of Life | 5 | 2023 | 2168 | 0.520 |
Why?
|
| Treatment Outcome | 22 | 2025 | 13103 | 0.520 |
Why?
|
| Robotics | 1 | 2018 | 110 | 0.520 |
Why?
|
| Drug Prescriptions | 2 | 2015 | 244 | 0.510 |
Why?
|
| Surface Properties | 1 | 2016 | 96 | 0.510 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 202 | 0.510 |
Why?
|
| Administration, Oral | 6 | 2025 | 719 | 0.500 |
Why?
|
| Interleukin-8 | 5 | 2017 | 214 | 0.500 |
Why?
|
| Genotype | 2 | 2021 | 2720 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2014 | 772 | 0.490 |
Why?
|
| Bifidobacterium | 3 | 2021 | 70 | 0.480 |
Why?
|
| Pyridines | 6 | 2024 | 250 | 0.480 |
Why?
|
| Health Facilities | 1 | 2016 | 67 | 0.480 |
Why?
|
| Voriconazole | 1 | 2015 | 34 | 0.480 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2015 | 59 | 0.470 |
Why?
|
| Infection Control | 3 | 2017 | 161 | 0.470 |
Why?
|
| Fungemia | 4 | 2007 | 23 | 0.460 |
Why?
|
| ADP Ribose Transferases | 3 | 2020 | 20 | 0.460 |
Why?
|
| Young Adult | 14 | 2025 | 9923 | 0.460 |
Why?
|
| Benzimidazoles | 5 | 2024 | 136 | 0.460 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 347 | 0.450 |
Why?
|
| Health Care Surveys | 2 | 2016 | 295 | 0.450 |
Why?
|
| Drug Interactions | 8 | 2019 | 259 | 0.440 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 99 | 0.440 |
Why?
|
| Mentors | 1 | 2016 | 164 | 0.430 |
Why?
|
| Liver Diseases | 1 | 2018 | 389 | 0.430 |
Why?
|
| Escherichia coli | 3 | 2022 | 1031 | 0.420 |
Why?
|
| Creatinine | 3 | 2013 | 418 | 0.420 |
Why?
|
| Family Characteristics | 1 | 2014 | 91 | 0.420 |
Why?
|
| Leadership | 1 | 2016 | 246 | 0.410 |
Why?
|
| Pilot Projects | 7 | 2021 | 1469 | 0.410 |
Why?
|
| Catheter-Related Infections | 2 | 2012 | 139 | 0.410 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2006 | 1163 | 0.400 |
Why?
|
| HIV Infections | 3 | 2021 | 2076 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 2855 | 0.400 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2024 | 359 | 0.400 |
Why?
|
| Piperacillin | 3 | 2010 | 14 | 0.390 |
Why?
|
| Medication Therapy Management | 1 | 2012 | 27 | 0.390 |
Why?
|
| Animals | 19 | 2025 | 36222 | 0.390 |
Why?
|
| Daptomycin | 1 | 2012 | 15 | 0.390 |
Why?
|
| Patient Readmission | 2 | 2016 | 430 | 0.390 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2024 | 545 | 0.380 |
Why?
|
| Time Factors | 11 | 2021 | 6544 | 0.380 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 938 | 0.380 |
Why?
|
| Chromatography, Liquid | 2 | 2024 | 245 | 0.380 |
Why?
|
| Phylogeny | 5 | 2025 | 781 | 0.380 |
Why?
|
| Esomeprazole | 1 | 2012 | 32 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1714 | 0.370 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2012 | 47 | 0.370 |
Why?
|
| Electronic Health Records | 1 | 2019 | 804 | 0.370 |
Why?
|
| Sunlight | 1 | 2011 | 26 | 0.370 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 1110 | 0.370 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 1174 | 0.370 |
Why?
|
| Medication Adherence | 1 | 2015 | 343 | 0.370 |
Why?
|
| Ambulatory Care | 1 | 2015 | 415 | 0.360 |
Why?
|
| Gastrointestinal Diseases | 3 | 2010 | 353 | 0.360 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 1166 | 0.360 |
Why?
|
| Enterococcus | 2 | 2014 | 31 | 0.360 |
Why?
|
| Fomites | 1 | 2011 | 5 | 0.360 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 543 | 0.360 |
Why?
|
| Odds Ratio | 6 | 2018 | 1254 | 0.360 |
Why?
|
| Sensitivity and Specificity | 7 | 2024 | 2142 | 0.350 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1067 | 0.350 |
Why?
|
| Prognosis | 7 | 2021 | 5044 | 0.350 |
Why?
|
| Acinetobacter Infections | 1 | 2011 | 36 | 0.340 |
Why?
|
| Mutation | 5 | 2024 | 6343 | 0.340 |
Why?
|
| Staphylococcal Infections | 3 | 2019 | 573 | 0.340 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 128 | 0.340 |
Why?
|
| Intestinal Secretions | 1 | 2010 | 4 | 0.340 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 256 | 0.330 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 3043 | 0.330 |
Why?
|
| Bacterial Adhesion | 2 | 2020 | 106 | 0.330 |
Why?
|
| Gastrointestinal Tract | 2 | 2023 | 237 | 0.330 |
Why?
|
| Patients | 1 | 2011 | 127 | 0.330 |
Why?
|
| Anticoagulants | 1 | 2015 | 628 | 0.320 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 237 | 0.320 |
Why?
|
| Vitamin D | 1 | 2011 | 180 | 0.320 |
Why?
|
| Logistic Models | 6 | 2016 | 1864 | 0.320 |
Why?
|
| Clinical Trials as Topic | 9 | 2019 | 1156 | 0.320 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2010 | 67 | 0.320 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 45 | 0.320 |
Why?
|
| Methicillin Resistance | 2 | 2007 | 118 | 0.320 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2021 | 272 | 0.310 |
Why?
|
| Incidence | 5 | 2019 | 3395 | 0.310 |
Why?
|
| Drug Utilization | 4 | 2020 | 169 | 0.300 |
Why?
|
| Microbiological Techniques | 2 | 2019 | 34 | 0.300 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 1420 | 0.300 |
Why?
|
| Azithromycin | 2 | 1999 | 46 | 0.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 631 | 0.300 |
Why?
|
| Cell Wall | 2 | 2021 | 40 | 0.300 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2008 | 460 | 0.300 |
Why?
|
| Toxemia | 2 | 2020 | 3 | 0.290 |
Why?
|
| Adolescent | 14 | 2025 | 20573 | 0.290 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1849 | 0.290 |
Why?
|
| Delivery of Health Care | 4 | 2021 | 683 | 0.290 |
Why?
|
| Cefuroxime | 1 | 2007 | 15 | 0.280 |
Why?
|
| Colony Count, Microbial | 3 | 2019 | 86 | 0.280 |
Why?
|
| Double-Blind Method | 4 | 2025 | 1661 | 0.280 |
Why?
|
| Hospitals, Community | 2 | 2020 | 55 | 0.280 |
Why?
|
| Treatment Failure | 3 | 2021 | 362 | 0.280 |
Why?
|
| Aminoglycosides | 4 | 2017 | 46 | 0.270 |
Why?
|
| United States | 8 | 2023 | 11722 | 0.270 |
Why?
|
| Immunization Programs | 2 | 2007 | 65 | 0.270 |
Why?
|
| Outpatients | 2 | 2022 | 275 | 0.270 |
Why?
|
| Hospital Costs | 2 | 2019 | 187 | 0.270 |
Why?
|
| Tertiary Care Centers | 3 | 2018 | 271 | 0.270 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 469 | 0.270 |
Why?
|
| Case-Control Studies | 5 | 2018 | 3418 | 0.260 |
Why?
|
| Canada | 2 | 2023 | 343 | 0.260 |
Why?
|
| Sternum | 1 | 2006 | 53 | 0.250 |
Why?
|
| Academic Medical Centers | 4 | 2020 | 336 | 0.250 |
Why?
|
| Blood | 2 | 2018 | 108 | 0.250 |
Why?
|
| Breath Tests | 2 | 2004 | 181 | 0.250 |
Why?
|
| Peptides, Cyclic | 4 | 2025 | 57 | 0.250 |
Why?
|
| Disinfectants | 2 | 2019 | 28 | 0.250 |
Why?
|
| Health Personnel | 1 | 2011 | 549 | 0.250 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2018 | 135 | 0.240 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 92 | 0.240 |
Why?
|
| Drug Therapy, Combination | 5 | 2011 | 1165 | 0.240 |
Why?
|
| Macrolides | 2 | 2003 | 31 | 0.230 |
Why?
|
| Body Mass Index | 1 | 2011 | 1713 | 0.230 |
Why?
|
| Dysbiosis | 2 | 2024 | 145 | 0.230 |
Why?
|
| Genes, Bacterial | 2 | 2019 | 218 | 0.230 |
Why?
|
| Administration, Intravenous | 1 | 2025 | 162 | 0.230 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2025 | 44 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 3740 | 0.230 |
Why?
|
| Telephone | 2 | 2015 | 127 | 0.220 |
Why?
|
| Dogs | 3 | 2022 | 672 | 0.220 |
Why?
|
| Asthma | 3 | 2003 | 807 | 0.220 |
Why?
|
| Hospital Mortality | 3 | 2021 | 1100 | 0.220 |
Why?
|
| Critical Illness | 2 | 2022 | 629 | 0.210 |
Why?
|
| Nonprescription Drugs | 1 | 2004 | 54 | 0.210 |
Why?
|
| General Surgery | 1 | 2006 | 220 | 0.210 |
Why?
|
| Phagocytosis | 1 | 2024 | 194 | 0.210 |
Why?
|
| Pharmaceutical Preparations | 1 | 2004 | 91 | 0.200 |
Why?
|
| Toxoids | 1 | 2023 | 7 | 0.200 |
Why?
|
| Nitroimidazoles | 1 | 2023 | 44 | 0.200 |
Why?
|
| Fusobacteria | 1 | 2022 | 1 | 0.200 |
Why?
|
| Microscopy | 1 | 2024 | 123 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 491 | 0.200 |
Why?
|
| Certification | 1 | 2003 | 73 | 0.200 |
Why?
|
| Freeze Drying | 1 | 2022 | 16 | 0.200 |
Why?
|
| Fusobacterium Infections | 1 | 2022 | 14 | 0.200 |
Why?
|
| Microbial Viability | 3 | 2017 | 43 | 0.200 |
Why?
|
| Bangladesh | 2 | 2019 | 36 | 0.200 |
Why?
|
| Carrier State | 2 | 2021 | 78 | 0.190 |
Why?
|
| Renal Dialysis | 2 | 2006 | 893 | 0.190 |
Why?
|
| Rhinitis | 1 | 2003 | 38 | 0.190 |
Why?
|
| Virulence | 2 | 2020 | 278 | 0.190 |
Why?
|
| Drug Resistance | 2 | 2019 | 262 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 252 | 0.190 |
Why?
|
| Interleukin-1beta | 1 | 2023 | 167 | 0.190 |
Why?
|
| Drug Resistance, Microbial | 3 | 2011 | 198 | 0.190 |
Why?
|
| Vaccination | 2 | 2007 | 1019 | 0.190 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2022 | 94 | 0.190 |
Why?
|
| Models, Psychological | 2 | 2020 | 145 | 0.190 |
Why?
|
| Program Evaluation | 3 | 2020 | 460 | 0.190 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 723 | 0.190 |
Why?
|
| Ketolides | 1 | 2001 | 4 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 906 | 0.180 |
Why?
|
| Cytokines | 5 | 2021 | 1378 | 0.180 |
Why?
|
| Cunninghamella | 1 | 2001 | 3 | 0.180 |
Why?
|
| Sinusitis | 1 | 2003 | 114 | 0.180 |
Why?
|
| Bronchiolitis | 1 | 2003 | 123 | 0.180 |
Why?
|
| Virginiamycin | 1 | 2001 | 3 | 0.180 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 527 | 0.180 |
Why?
|
| Binding Sites | 1 | 2024 | 1378 | 0.180 |
Why?
|
| Thailand | 2 | 2011 | 43 | 0.180 |
Why?
|
| Mammals | 1 | 2023 | 282 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2001 | 314 | 0.180 |
Why?
|
| Lung Diseases, Fungal | 1 | 2001 | 32 | 0.180 |
Why?
|
| Enterococcus faecalis | 1 | 2001 | 49 | 0.170 |
Why?
|
| Mucormycosis | 1 | 2001 | 32 | 0.170 |
Why?
|
| Gram-Negative Bacteria | 2 | 2016 | 74 | 0.170 |
Why?
|
| Pharmacies | 1 | 2020 | 15 | 0.170 |
Why?
|
| Fusobacterium nucleatum | 1 | 2020 | 25 | 0.170 |
Why?
|
| Chloride Channels | 2 | 2012 | 63 | 0.170 |
Why?
|
| Decision Making | 1 | 2006 | 702 | 0.170 |
Why?
|
| Serologic Tests | 2 | 2018 | 128 | 0.170 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 325 | 0.170 |
Why?
|
| Adhesins, Bacterial | 1 | 2020 | 75 | 0.170 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 791 | 0.170 |
Why?
|
| Absenteeism | 1 | 2020 | 19 | 0.170 |
Why?
|
| Oxazolidinones | 2 | 2017 | 34 | 0.160 |
Why?
|
| Travel | 2 | 2012 | 125 | 0.160 |
Why?
|
| Prednisone | 1 | 2000 | 256 | 0.160 |
Why?
|
| Zebrafish | 1 | 2023 | 422 | 0.160 |
Why?
|
| Colitis | 1 | 2022 | 164 | 0.160 |
Why?
|
| Enteritis | 1 | 2020 | 37 | 0.160 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 131 | 0.160 |
Why?
|
| Encephalitis | 1 | 2001 | 122 | 0.160 |
Why?
|
| Preceptorship | 1 | 2020 | 31 | 0.160 |
Why?
|
| Bacterial Typing Techniques | 1 | 2020 | 104 | 0.160 |
Why?
|
| Staphylococcus epidermidis | 1 | 2019 | 40 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3363 | 0.160 |
Why?
|
| Jejunum | 1 | 2020 | 129 | 0.160 |
Why?
|
| Tosyl Compounds | 1 | 1999 | 24 | 0.160 |
Why?
|
| Glucose | 2 | 2021 | 917 | 0.160 |
Why?
|
| Leukotriene Antagonists | 1 | 1999 | 18 | 0.160 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1999 | 3 | 0.150 |
Why?
|
| Serotonin | 1 | 2020 | 223 | 0.150 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2019 | 27 | 0.150 |
Why?
|
| Smoking | 2 | 2004 | 944 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 44 | 0.150 |
Why?
|
| Naphthyridines | 1 | 1999 | 10 | 0.150 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 491 | 0.150 |
Why?
|
| Immunoglobulin G | 4 | 2023 | 790 | 0.150 |
Why?
|
| Bacteriological Techniques | 1 | 2019 | 88 | 0.150 |
Why?
|
| Child | 11 | 2023 | 25868 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 251 | 0.150 |
Why?
|
| Teaching | 1 | 2020 | 201 | 0.150 |
Why?
|
| Cost Savings | 1 | 2019 | 75 | 0.150 |
Why?
|
| Hospitals, Teaching | 2 | 2009 | 115 | 0.150 |
Why?
|
| Risk | 2 | 2014 | 782 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 283 | 0.150 |
Why?
|
| Clinical Audit | 1 | 2018 | 5 | 0.140 |
Why?
|
| Glucosyltransferases | 3 | 2017 | 50 | 0.140 |
Why?
|
| Azathioprine | 1 | 1998 | 39 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 618 | 0.140 |
Why?
|
| Pneumonia, Bacterial | 1 | 1999 | 81 | 0.140 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 62 | 0.140 |
Why?
|
| Societies, Pharmaceutical | 2 | 2015 | 16 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2000 | 401 | 0.140 |
Why?
|
| Barbiturates | 1 | 1997 | 7 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2018 | 1236 | 0.140 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 430 | 0.140 |
Why?
|
| Imipramine | 1 | 1997 | 18 | 0.140 |
Why?
|
| Propensity Score | 1 | 2019 | 263 | 0.140 |
Why?
|
| Medication Systems, Hospital | 1 | 2017 | 46 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 748 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 1340 | 0.140 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1997 | 26 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2019 | 117 | 0.140 |
Why?
|
| Rats | 2 | 2025 | 3851 | 0.140 |
Why?
|
| Calcium Signaling | 1 | 2019 | 253 | 0.140 |
Why?
|
| Drug Hypersensitivity | 1 | 1998 | 100 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 1214 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 1240 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1303 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2018 | 245 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2020 | 1185 | 0.120 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2017 | 140 | 0.120 |
Why?
|
| Mucin-2 | 3 | 2020 | 42 | 0.120 |
Why?
|
| Mucositis | 1 | 2015 | 19 | 0.120 |
Why?
|
| Autophagy | 1 | 2019 | 431 | 0.120 |
Why?
|
| Tertiary Healthcare | 1 | 2015 | 20 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 79 | 0.120 |
Why?
|
| Optical Imaging | 1 | 2016 | 74 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 319 | 0.120 |
Why?
|
| beta-Glucans | 1 | 2015 | 20 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 213 | 0.120 |
Why?
|
| Health Resources | 1 | 2016 | 127 | 0.120 |
Why?
|
| Triose-Phosphate Isomerase | 1 | 2015 | 7 | 0.120 |
Why?
|
| Genome, Bacterial | 3 | 2021 | 212 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.120 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2022 | 94 | 0.120 |
Why?
|
| In Vitro Techniques | 2 | 2019 | 961 | 0.120 |
Why?
|
| Costs and Cost Analysis | 2 | 2007 | 166 | 0.120 |
Why?
|
| International Normalized Ratio | 1 | 2015 | 45 | 0.120 |
Why?
|
| Electronic Mail | 1 | 2015 | 43 | 0.120 |
Why?
|
| Biomass | 2 | 2019 | 23 | 0.120 |
Why?
|
| Nanospheres | 1 | 2014 | 7 | 0.110 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2014 | 8 | 0.110 |
Why?
|
| Meningitis | 1 | 2015 | 101 | 0.110 |
Why?
|
| Automation | 2 | 2017 | 63 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 149 | 0.110 |
Why?
|
| Thiazoles | 2 | 2017 | 104 | 0.110 |
Why?
|
| Global Health | 1 | 2019 | 622 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2015 | 158 | 0.110 |
Why?
|
| Data Collection | 2 | 2014 | 396 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2015 | 93 | 0.110 |
Why?
|
| Glutamine | 1 | 2015 | 217 | 0.110 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 102 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 3 | 2023 | 253 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2015 | 153 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 171 | 0.110 |
Why?
|
| Mice | 6 | 2025 | 18936 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 679 | 0.110 |
Why?
|
| Disease Outbreaks | 2 | 2018 | 330 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 5443 | 0.100 |
Why?
|
| Specialization | 1 | 2014 | 81 | 0.100 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 94 | 0.100 |
Why?
|
| Biomarkers | 3 | 2021 | 3415 | 0.100 |
Why?
|
| Secondary Prevention | 2 | 2012 | 223 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2020 | 3718 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2014 | 68 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 179 | 0.100 |
Why?
|
| Organizational Policy | 1 | 2013 | 54 | 0.100 |
Why?
|
| Serum | 1 | 2013 | 46 | 0.100 |
Why?
|
| Genomics | 1 | 2021 | 1676 | 0.100 |
Why?
|
| United Kingdom | 2 | 2010 | 241 | 0.100 |
Why?
|
| Biological Therapy | 1 | 2012 | 24 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 809 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2012 | 44 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1049 | 0.100 |
Why?
|
| Thienamycins | 1 | 2012 | 14 | 0.100 |
Why?
|
| Creatine Kinase | 1 | 2012 | 63 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2015 | 415 | 0.100 |
Why?
|
| Heme | 2 | 2023 | 53 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2012 | 105 | 0.090 |
Why?
|
| Inflammation | 1 | 2020 | 1559 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2024 | 4917 | 0.090 |
Why?
|
| Fosfomycin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Imipenem | 1 | 2011 | 9 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2025 | 404 | 0.090 |
Why?
|
| APACHE | 1 | 2011 | 57 | 0.090 |
Why?
|
| Alcohols | 1 | 2011 | 17 | 0.090 |
Why?
|
| Colistin | 1 | 2011 | 33 | 0.090 |
Why?
|
| Child, Preschool | 6 | 2023 | 14873 | 0.090 |
Why?
|
| Colon | 1 | 2014 | 373 | 0.090 |
Why?
|
| Immunoglobulin A | 2 | 2023 | 215 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 235 | 0.090 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 947 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 185 | 0.090 |
Why?
|
| Brazil | 2 | 2022 | 135 | 0.080 |
Why?
|
| Nitro Compounds | 1 | 2010 | 19 | 0.080 |
Why?
|
| Ireland | 1 | 2010 | 34 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 77 | 0.080 |
Why?
|
| Professional Practice | 1 | 2010 | 42 | 0.080 |
Why?
|
| Cell Line | 1 | 2015 | 2853 | 0.080 |
Why?
|
| Germ-Free Life | 2 | 2020 | 65 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 221 | 0.080 |
Why?
|
| Hepatic Encephalopathy | 1 | 2010 | 94 | 0.080 |
Why?
|
| Agar | 2 | 2021 | 15 | 0.080 |
Why?
|
| Phenotype | 4 | 2025 | 4577 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 606 | 0.080 |
Why?
|
| Colorimetry | 1 | 2008 | 18 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 288 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 753 | 0.070 |
Why?
|
| Blotting, Southern | 1 | 2008 | 218 | 0.070 |
Why?
|
| Publications | 1 | 2008 | 35 | 0.070 |
Why?
|
| Peer Review | 1 | 2008 | 41 | 0.070 |
Why?
|
| Critical Care | 1 | 2014 | 698 | 0.070 |
Why?
|
| Societies | 2 | 2018 | 27 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 294 | 0.070 |
Why?
|
| Penicillanic Acid | 1 | 2008 | 10 | 0.070 |
Why?
|
| Linear Models | 2 | 2008 | 719 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2006 | 330 | 0.070 |
Why?
|
| Coagulase | 1 | 2007 | 23 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2010 | 395 | 0.070 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2010 | 222 | 0.070 |
Why?
|
| Vero Cells | 2 | 2020 | 113 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2012 | 578 | 0.070 |
Why?
|
| Staphylococcus | 1 | 2007 | 69 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 340 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 40 | 0.070 |
Why?
|
| Isoelectric Focusing | 1 | 2007 | 24 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2011 | 1584 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2007 | 59 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 1137 | 0.070 |
Why?
|
| DNA Fingerprinting | 1 | 2007 | 107 | 0.070 |
Why?
|
| Antibodies, Bacterial | 2 | 2022 | 401 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 304 | 0.070 |
Why?
|
| Dysentery | 1 | 2006 | 5 | 0.070 |
Why?
|
| Organoids | 2 | 2020 | 299 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 814 | 0.070 |
Why?
|
| Hospitals, General | 1 | 2006 | 24 | 0.070 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2007 | 116 | 0.060 |
Why?
|
| Probiotics | 2 | 2025 | 229 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1033 | 0.060 |
Why?
|
| Hospital Departments | 1 | 2006 | 15 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2006 | 113 | 0.060 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 305 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2007 | 436 | 0.060 |
Why?
|
| Caco-2 Cells | 2 | 2016 | 95 | 0.060 |
Why?
|
| Physicians | 1 | 2012 | 640 | 0.060 |
Why?
|
| Point Mutation | 1 | 2007 | 358 | 0.060 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2025 | 18 | 0.060 |
Why?
|
| Cations, Divalent | 1 | 2005 | 21 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1136 | 0.060 |
Why?
|
| Curriculum | 2 | 2020 | 768 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 606 | 0.060 |
Why?
|
| Survivors | 1 | 2007 | 358 | 0.060 |
Why?
|
| Refuse Disposal | 1 | 2004 | 6 | 0.060 |
Why?
|
| Carbon | 1 | 2025 | 98 | 0.060 |
Why?
|
| Oxadiazoles | 1 | 2024 | 25 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1830 | 0.060 |
Why?
|
| Intestinal Absorption | 1 | 2005 | 191 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1325 | 0.050 |
Why?
|
| Gene Expression | 1 | 2009 | 1608 | 0.050 |
Why?
|
| Enteral Nutrition | 1 | 2006 | 269 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2004 | 57 | 0.050 |
Why?
|
| Nitrites | 1 | 2004 | 49 | 0.050 |
Why?
|
| Phosphatidylglycerols | 1 | 2003 | 8 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2004 | 139 | 0.050 |
Why?
|
| Deoxycholic Acid | 1 | 2003 | 13 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2003 | 39 | 0.050 |
Why?
|
| Antitoxins | 1 | 2023 | 7 | 0.050 |
Why?
|
| Anaerobiosis | 1 | 2022 | 15 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2003 | 99 | 0.050 |
Why?
|
| Body Weight | 1 | 2007 | 1035 | 0.050 |
Why?
|
| Heart Failure | 1 | 2016 | 2428 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2021 | 310 | 0.050 |
Why?
|
| Bronchitis | 1 | 2003 | 33 | 0.050 |
Why?
|
| Vitreous Body | 1 | 2003 | 101 | 0.050 |
Why?
|
| Nasal Polyps | 1 | 2003 | 25 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2006 | 404 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2002 | 69 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2007 | 498 | 0.050 |
Why?
|
| North America | 1 | 2022 | 265 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2007 | 1072 | 0.050 |
Why?
|
| Metabolome | 1 | 2024 | 322 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2001 | 104 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2003 | 130 | 0.040 |
Why?
|
| DNA | 1 | 2007 | 1676 | 0.040 |
Why?
|
| Acids | 1 | 2021 | 31 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 684 | 0.040 |
Why?
|
| Flagella | 1 | 2020 | 29 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2020 | 45 | 0.040 |
Why?
|
| Enterochromaffin Cells | 1 | 2020 | 11 | 0.040 |
Why?
|
| Bioreactors | 1 | 2020 | 44 | 0.040 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2001 | 95 | 0.040 |
Why?
|
| Receptors, Serotonin | 1 | 2020 | 43 | 0.040 |
Why?
|
| Behavior Control | 1 | 2020 | 11 | 0.040 |
Why?
|
| Symbiosis | 1 | 2021 | 102 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2020 | 71 | 0.040 |
Why?
|
| Operon | 1 | 2020 | 54 | 0.040 |
Why?
|
| o-Phthalaldehyde | 1 | 2019 | 3 | 0.040 |
Why?
|
| Acetates | 1 | 2020 | 80 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 2020 | 49 | 0.040 |
Why?
|
| Sodium Hypochlorite | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cell Shape | 1 | 2020 | 70 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2003 | 266 | 0.040 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2019 | 34 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2019 | 37 | 0.040 |
Why?
|
| Bacteria, Anaerobic | 1 | 1999 | 10 | 0.040 |
Why?
|
| Cost Control | 2 | 2011 | 24 | 0.040 |
Why?
|
| Ofloxacin | 1 | 1999 | 32 | 0.040 |
Why?
|
| Inpatients | 2 | 2017 | 551 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 164 | 0.040 |
Why?
|
| Levofloxacin | 1 | 1999 | 48 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 213 | 0.040 |
Why?
|
| Phenylcarbamates | 1 | 1999 | 16 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 224 | 0.040 |
Why?
|
| Economics, Pharmaceutical | 1 | 1999 | 9 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2019 | 86 | 0.040 |
Why?
|
| MEDLINE | 1 | 1999 | 20 | 0.040 |
Why?
|
| Mucins | 1 | 2019 | 77 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 293 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2020 | 136 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 35 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2018 | 62 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1323 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2018 | 72 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2019 | 106 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 483 | 0.040 |
Why?
|
| Students | 1 | 2020 | 263 | 0.040 |
Why?
|
| Infectious Disease Medicine | 1 | 2018 | 11 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 230 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2019 | 152 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 839 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 389 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1090 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2019 | 180 | 0.040 |
Why?
|
| Professional Role | 2 | 2010 | 74 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 332 | 0.040 |
Why?
|
| Indoles | 1 | 1999 | 202 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 329 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 265 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 498 | 0.030 |
Why?
|
| Behavior | 1 | 2017 | 75 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1999 | 123 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2017 | 48 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2020 | 522 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 569 | 0.030 |
Why?
|
| Attitude | 1 | 2017 | 122 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 2092 | 0.030 |
Why?
|
| Benzopyrans | 1 | 2017 | 21 | 0.030 |
Why?
|
| Sulfonamides | 1 | 1999 | 289 | 0.030 |
Why?
|
| Depsipeptides | 1 | 2017 | 11 | 0.030 |
Why?
|
| Nurses | 1 | 2017 | 77 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2001 | 494 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2017 | 130 | 0.030 |
Why?
|
| Thiophenes | 1 | 2017 | 72 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 68 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 300 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 234 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2001 | 575 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2001 | 824 | 0.030 |
Why?
|
| Culture Media | 1 | 2016 | 183 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1193 | 0.030 |
Why?
|
| Diverticulitis, Colonic | 1 | 2015 | 7 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 260 | 0.030 |
Why?
|
| Pregnancy | 1 | 2008 | 7602 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 83 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 439 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 593 | 0.030 |
Why?
|
| Louisiana | 1 | 2015 | 137 | 0.030 |
Why?
|
| Blood Preservation | 1 | 2015 | 31 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 128 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 536 | 0.030 |
Why?
|
| Candida tropicalis | 1 | 2015 | 17 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2015 | 68 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 77 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2015 | 63 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 175 | 0.030 |
Why?
|
| Biological Assay | 1 | 2015 | 111 | 0.030 |
Why?
|
| Candida albicans | 1 | 2015 | 89 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1730 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 1597 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1997 | 485 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 779 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 1184 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 384 | 0.020 |
Why?
|
| Infant | 2 | 2023 | 13243 | 0.020 |
Why?
|
| Psychometrics | 1 | 2016 | 694 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2011 | 33 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2011 | 48 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 416 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 932 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 498 | 0.020 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 18 | 0.020 |
Why?
|
| beta-Lactams | 1 | 2010 | 56 | 0.020 |
Why?
|
| Pharmacy Administration | 1 | 2010 | 2 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2010 | 129 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 243 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 156 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3794 | 0.020 |
Why?
|
| Drug Costs | 1 | 2006 | 66 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 201 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2011 | 551 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 834 | 0.010 |
Why?
|
| Intestines | 1 | 2009 | 599 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 241 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 251 | 0.010 |
Why?
|
| Dyslipidemias | 1 | 2007 | 246 | 0.010 |
Why?
|
| Sex Factors | 1 | 2007 | 1353 | 0.010 |
Why?
|
| Blood Bactericidal Activity | 1 | 2002 | 17 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 284 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 710 | 0.010 |
Why?
|
| Retinal Ganglion Cells | 1 | 2003 | 119 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 467 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2001 | 119 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2001 | 144 | 0.010 |
Why?
|
| Retinal Diseases | 1 | 2003 | 182 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 207 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 2956 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2005 | 519 | 0.010 |
Why?
|
| Forecasting | 1 | 2001 | 374 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 205 | 0.010 |
Why?
|
| Bacteroides | 1 | 1999 | 37 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 565 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8632 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1420 | 0.010 |
Why?
|